~29 spots leftby Dec 2026

Proton Beam Radiation for Wilms Tumor

Recruiting in Palo Alto (17 mi)
MJ
Overseen byMatthew J Krasin, MD
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: St. Jude Children's Research Hospital
Disqualifiers: Prior radiation, Unfavorable histology, others
No Placebo Group
Prior Safety Data
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

Participants are being asked to take part in this clinical trial, a type of research study, because the participants have a Wilms Tumor cancer. Primary Objectives To determine whether delivery of proton beam radiation to a conformal reduced target volume in the flank allows normal flank growth compared to the contralateral untreated side and non-irradiated patients. Secondary Objectives To deliver proton beam radiation to a conformal reduced target volume (partial kidney proton beam radiation therapy) in the affected kidney(s) for patients with Stage V (bilateral Wilms tumor) and specific involved surgical margins yielding no reduction in the high control rates seen with more traditional flank / whole kidney fields. Exploratory Objectives * Study the feasibility of sparing the residual kidney, spine and liver in patients requiring whole abdomen radiation therapy using either a proton beam treatment technique or intensity-modulated radiation therapy ( IMRT) photon based technique. * Study the feasibility of delivering whole lung radiation therapy with proton beams with the goals of sparing the developing breast tissue, heart structures, thyroid and liver. * Develop simultaneous xenografts and organoid models from the same starting material to study Wilms tumor biology and compare responses to chemotherapeutic agents. * Define the evolution of organ specific (kidney, liver, pancreas, etc.) abnormalities (laboratory studies) as an early marker of possible late end organ damage and their relationship to radiation. * Study and evaluate impact of proton therapy on the musculoskeletal system and physical performance and compare with photon therapy cases treated with classical treatment fields. * Assess CTC-AE and Pediatric Patient Reported Outcomes during radiation and in follow-up, correlating with disease, treatment and patient variables. * Correlate quantitative MRI values, including apparent diffusion coefficient (ADC) values, with histopathology findings post-surgery in children with (bilateral) Wilms. * Assess daily variations in proton range along each treatment beam using standard pre-treatment cone beam CT or on-treatment MR.

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.

What data supports the effectiveness of the treatment Proton Beam Radiation for Wilms Tumor?

Proton beam therapy (PBT) is considered a promising treatment for childhood cancers, including Wilms tumor, because it can target tumors more precisely and reduce radiation exposure to healthy tissues, potentially leading to fewer side effects. Studies suggest that PBT may be particularly beneficial for tumors in complex areas or those surrounded by sensitive tissues, which is often the case in pediatric cancers.12345

Is proton beam therapy generally safe for humans?

Proton beam therapy (PBT) is considered safe and is often used for treating childhood cancers and tumors near sensitive areas. Studies suggest it may reduce the risk of secondary cancers compared to traditional X-ray therapy.34678

How is Proton Beam Radiation different from other treatments for Wilms Tumor?

Proton Beam Radiation (PBT) is unique because it precisely targets tumors with minimal damage to surrounding healthy tissues, making it especially beneficial for treating childhood cancers like Wilms Tumor. This precision is due to the Bragg peak effect, where protons release most of their energy directly at the tumor site, reducing side effects compared to traditional radiation therapies.3491011

Research Team

MJ

Matthew J Krasin, MD

Principal Investigator

St. Jude Children's Research Hospital

Eligibility Criteria

This trial is for patients with a newly diagnosed Wilms Tumor, who haven't had abdominal radiation before. It's open to those who've only had specific initial chemotherapy or surgery, and are within certain time frames post-surgery. Pregnant women can't participate, nor can those unwilling to consent or previously treated with radiation in the areas targeted by this study.

Inclusion Criteria

I have not had radiation therapy targeted at my abdomen.
I have followed the specific chemotherapy plan outlined for my condition and may switch based on my response.
I am a woman who can have children and have a negative pregnancy test.
See 7 more

Exclusion Criteria

I have had radiation therapy before but may need it again for this trial.
Inability or unwillingness to provide written informed consent

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Chemotherapy

Participants undergo 6-12 weeks of induction chemotherapy before surgical resection

6-12 weeks

Surgical Resection

Participants undergo surgical resection at diagnosis or after induction chemotherapy

1 week

Adjuvant Radiation Therapy

Participants receive adjuvant proton beam radiation therapy based on stage and surgical findings

4-6 weeks

Systemic Therapy

Systemic therapy delivered in a standard of care manner according to histology and stage

Varies

Follow-up

Participants are monitored for safety and effectiveness after treatment

10 years

Treatment Details

Interventions

  • Proton Beam Radiation (PBRT) (Proton Beam Therapy)
Trial OverviewThe trial tests if proton beam radiation can be delivered more precisely to reduce side effects and allow normal growth of non-cancerous tissue compared to traditional methods. It also explores how well it spares healthy organs during whole abdomen therapy and assesses its impact on physical performance versus photon therapy.
Participant Groups
3Treatment groups
Active Control
Group I: Stage V Adjuvant RT:Active Control3 Interventions
Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT
Group II: Favorable Histology Stage I & II and FH Stage III/IVActive Control1 Intervention
Favorable Histology Stage I \& II and FH Stage III/IV Delayed Local Control with clear surgical margins and pathologically negative lymph nodes. Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
Group III: Stage III & IV Adjuvant RT and Stage VActive Control3 Interventions
Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT.

Proton Beam Radiation (PBRT) is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as Proton Therapy for:
  • Wilms tumor
  • Brain tumors
  • Breast cancer
  • Esophageal cancer
  • Eye cancer
  • Gynecological cancers
  • Head and neck cancer
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Pancreatic cancer
  • Prostate cancer
  • Rectal cancer
  • Sarcomas
  • Spinal cord tumors

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
St.Jude Children's Research HospitalMemphis, TN
Loading ...

Who Is Running the Clinical Trial?

St. Jude Children's Research Hospital

Lead Sponsor

Trials
451
Patients Recruited
5,326,000+

Findings from Research

Proton beam therapy in pediatric oncology.Merchant, TE.[2022]
Proton therapy using pencil beam scanning (PBS) significantly reduces radiation exposure to critical organs at risk (OAR) in patients with Wilms tumor, with mean doses to the contralateral kidney, bowel, and liver being much lower compared to traditional photon therapy.
In a study of 11 patients, PBS resulted in a mean dose of only 52 cGy to the contralateral kidney compared to 135 cGy with photons, indicating a potential for improved long-term health outcomes due to reduced toxicity.
Pencil beam scanning proton therapy for treatment of the retroperitoneum after nephrectomy for Wilms tumor: A dosimetric comparison study.Vogel, J., Lin, H., Both, S., et al.[2018]
Preliminary Experience of Treating Children and Young Adults With Image-Guided Proton Beam Therapy in India.Chilukuri, S., Burela, N., Uppuluri, R., et al.[2021]
Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018.Nogueira, LM., Jemal, A., Yabroff, KR., et al.[2022]
Clinical Implementation of Preoperative Short-Course Pencil Beam Scanning Proton Therapy for Patients With Rectal Cancer.Jeans, EB., Jethwa, KR., Harmsen, WS., et al.[2022]
Proton beam therapy (PBS) significantly reduces the risk of secondary malignancies (SM) compared to X-ray-based treatments like 3D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT), as shown in a study involving treatment plans for 17 patients.
The study found that PBS offers better protection for critical organs, such as the lungs and breasts, leading to lower estimated SM rates, making it a preferable option for treating thymic malignancies, especially in young female patients.
Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk.König, L., Hörner-Rieber, J., Forsthoefel, M., et al.[2022]
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.Lee, HJ., Macomber, MW., Spraker, MB., et al.[2019]
In a study of 68 patients with non-metastatic major salivary gland tumors treated with proton beam radiation therapy (PBRT), the 3-year locoregional control rate was an impressive 95.1%, indicating high effectiveness in managing the disease.
PBRT was well tolerated by patients, suggesting it is a safe treatment option for major salivary gland tumors, with overall survival rates reaching 96.1% over the same period.
Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy.Zakeri, K., Wang, H., Kang, JJ., et al.[2022]
Proton beam therapy (PBT) is feasible for treating infants with central nervous system tumors, showing promising short-term outcomes with a 3-year overall survival rate of 76.5% among 51 infants studied.
However, the treatment is associated with significant logistical challenges and potential for higher-grade toxicities, including late effects like endocrinopathy and hearing loss, highlighting the need for careful monitoring and longer follow-up to assess long-term impacts.
Feasibility of Proton Beam Therapy for Infants with Brain Tumours: Experiences from the Prospective KiProReg Registry Study.Jazmati, D., Steinmeier, T., Ahamd Khalil, D., et al.[2021]
Proton minibeam radiation therapy (pMBRT) shows promise for treating high-grade gliomas and meningiomas, potentially offering reduced side effects and improved tumor control compared to standard radiation methods, based on theoretical evaluations of treatment plans.
While pMBRT provides similar dose distributions for organs at risk and lower average doses for shallow organs, standard proton therapy plans demonstrated slightly better target homogeneity, indicating that further optimization of pMBRT is needed for clinical application.
First proton minibeam radiation therapy treatment plan evaluation.Lansonneur, P., Mammar, H., Nauraye, C., et al.[2021]
Proton minibeam radiation therapy (pMBRT) shows promise for treating brain, lung, and liver metastases, providing similar or better tumor coverage compared to stereotactic radiotherapy (SRT) while using fewer treatment fields.
pMBRT significantly reduces the dose to organs-at-risk and keeps normal tissue exposure below tolerance limits, suggesting a safer treatment option compared to conventional proton therapy.
Proton minibeam radiation therapy for treating metastases: A treatment plan study.Ortiz, R., Belshi, R., De Marzi, L., et al.[2023]

References

Proton beam therapy in pediatric oncology. [2022]
Pencil beam scanning proton therapy for treatment of the retroperitoneum after nephrectomy for Wilms tumor: A dosimetric comparison study. [2018]
Preliminary Experience of Treating Children and Young Adults With Image-Guided Proton Beam Therapy in India. [2021]
Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018. [2022]
Clinical Implementation of Preoperative Short-Course Pencil Beam Scanning Proton Therapy for Patients With Rectal Cancer. [2022]
Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. [2022]
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. [2019]
Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. [2022]
Feasibility of Proton Beam Therapy for Infants with Brain Tumours: Experiences from the Prospective KiProReg Registry Study. [2021]
First proton minibeam radiation therapy treatment plan evaluation. [2021]
11.United Statespubmed.ncbi.nlm.nih.gov
Proton minibeam radiation therapy for treating metastases: A treatment plan study. [2023]